HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Geographic tongue — Clinical Guidelines

Overview

Geographic tongue, also known as benign migratory glossitis, is a benign chronic inflammatory condition characterized by erythematous, map-like lesions on the tongue that change in size and shape over time without scarring 4.

Diagnosis

Clinical Presentation: Erythematous lesions with filiform papillae atrophy, forming a map-like pattern on the tongue 4.

No Specific Diagnostic Tests: Diagnosis is primarily clinical; no specific laboratory tests are required 4.

Management

No Specific Treatments: Management focuses on symptomatic relief and addressing triggers 4.

Avoid Triggers: Identify and avoid potential triggers such as spicy foods, acidic substances, and stress 4.

Topical Agents: Use of topical corticosteroids or antihistamines may provide symptomatic relief in some cases 4.

Special Populations

No Specific Guidelines: Limited evidence regarding geographic tongue in pregnancy, pediatrics, elderly, or specific comorbidities 4.

Key Recommendations

Clinical Diagnosis: Diagnosis is based on characteristic clinical appearance without the need for invasive testing (Evidence: Expert opinion 4).

Symptomatic Management: Focus on managing symptoms and identifying/avoiding potential triggers (Evidence: Expert opinion 4).

Monitoring: Regular follow-up to monitor lesion changes and ensure no complications arise (Evidence: Expert opinion 4).

References

1 Kailani Z, Mihalache A, Popovic MM, Kertes PJ, Muni RH. Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study. American journal of ophthalmology 2025. link 2 Patel NA, Hoyek S, Al-Khersan H, Yannuzzi NA, Smiddy WE. A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan. Ophthalmology. Retina 2024. link 3 Danzig CJ, Khanani AM, Kaiser PK, Chang MA, Kovach JL, Lally DR et al.. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. Ophthalmology. Retina 2024. link 4 Ogueta C I, Ramírez P M, Jiménez O C, Cifuentes M M. Geographic Tongue: What a Dermatologist Should Know. Actas dermo-sifiliograficas 2019. link 5 Rosen AC, Gavrilovic IT, Balagula Y, Ramaswamy V, Dickler MN, Dunkel IJ et al.. In reply. The oncologist 2013. link 6 Dupre A, Christol B, Lassere J, France T. Geographic lip: a variant of geopgraphic tongue. Cutis 1976. link

Geographic tongue